Veracyte, Inc. (Nasdaq: VCYT), a leading cancer diagnostics company, today announced results from the ENZAMET trial presented at the 2026 ASCO Annual Meeting. The analysis demonstrates that the ...
Survival and hematologic outcomes in prostate cancer patients with radiation cystitis receiving hyperbaric oxygen therapy: A propensity-matched analysis. This is an ASCO Meeting Abstract from the 2026 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results